ClinicalTrials.gg
CompletedNCT00051259Updated Oct 4, 2010

Effects of Antidepressants on Sexual Functioning

A Phase 3 interventional study of Extended-Release Bupropion Hydrochloride in Major Depressive Disorder (MDD), sponsored by GlaxoSmithKline. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-10-04.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing bupropion in Depressive Disorder, Major — 1 open to participants now, 3 under way, none of them phase 3. Bupropion · Depressive Disorder, Major.

Enrollment
5th of 37
420 · median 74
Started
2003
with 1 other
Phase 3
7 of 37
none open now
Registered
1st of 37
by date
Lead sponsor
5 of 37
GlaxoSmithKline

Among the 37 studies testing bupropion in Depressive Disorder, Major, this one is the 5th largest by enrollment, is one of 2 that started in 2003, is one of 7 in phase 3, and was the 1st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 37 studies testing bupropion in Depressive Disorder, Major is open now. Recruiting first, the newest first:

About bupropion

Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing bupropion in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this trial is to study the effects of two depression medications on sexual functioning.

03

Conditions studied

  • Major Depressive Disorder (MDD)

Keywords

  • depression
  • MDD
  • sexual dysfunction
  • orgasm disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of Major Depressive Disorder (MDD) with current duration lasting 12 weeks but no greater than 2 years.
  • Subjects must engage in sexual activity that leads to orgasm at least once every two weeks.
  • Subject must have normal orgasmic function and be willing to discuss with investigator.

Exclusion criteria

Exclusion Criteria:

  • Subjects that have arousal or orgasm dysfunction.
  • Has previously failed to respond to two adequate trials of antidepressants in past 2 years.
  • Subject has other unstable medical disorders.
  • Subject has a positive urine test for illicit drug use at screening.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
420 participants
06

What researchers measure

Primary outcomes

  1. Percentage of subjects with orgasm dysfunction. Change in HAMD-17 total score.

Secondary outcomes

  1. Percent of subjects in remission, HAMD-17. Changes in Sexual Functioning Questionnaire. Percent of responders, HAMD-17 CGI-I and CGI-S.

07

Study locations

23 sites
  • GSK Investigational Site
    Berkeley, California 94709, United States
  • GSK Investigational Site
    Beverly Hills, California 90210, United States
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    Oceanside, California 92056, United States
  • GSK Investigational Site
    Coral Springs, Florida 33065, United States
  • GSK Investigational Site
    Jacksonville, Florida 32216, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Terre Haute, Indiana 47802, United States
  • GSK Investigational Site
    Baltimore, Maryland 21208, United States
  • GSK Investigational Site
    Rockville, Maryland 20852, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55454, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Cleveland, Ohio 44109, United States
  • GSK Investigational Site
    Toledo, Ohio 43623, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74135, United States
  • GSK Investigational Site
    Eugene, Oregon 97401, United States
  • GSK Investigational Site
    Portland, Oregon 97210, United States
  • GSK Investigational Site
    Lincoln, Rhode Island 02865-4208, United States
  • GSK Investigational Site
    Charleston, South Carolina 29407, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
  • GSK Investigational Site
    Richmond, Virginia 23294, United States
  • GSK Investigational Site
    Madison, Wisconsin 53719, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003, a primary completion of Jun 2004 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2003
First posted
Jan 8, 2003
Start
Jan 2003
Primary completionActual
Jun 2004
CompletionActual
Jun 2004
Last update
Oct 4, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00051259
Lead sponsor
GlaxoSmithKline
First posted
Jan 8, 2003
Start date
Jan 2003
Primary completion
Jun 2004
Completion
Jun 2004
Last update
Oct 4, 2010

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion